| Patents for A61P 17 - Drugs for dermatological disorders (106,455) |
|---|
| 07/14/2005 | WO2005063705A1 Benzene compounds disubstituted with cyclic groups at the 1- and 2-positions |
| 07/14/2005 | WO2005063279A1 Means for stimulation and activation of hair growth by il-15 |
| 07/14/2005 | WO2005063207A1 Nonaqueous gel preparation for external use |
| 07/14/2005 | WO2005063196A1 Skin moisturizing agent for oral intake and functional foods and drinks |
| 07/14/2005 | WO2005063193A1 Combination set and method for the bio-regenerative treatment of skin |
| 07/14/2005 | WO2005063191A1 Topical depigmenting formulations comprising an extract of bellis perennis |
| 07/14/2005 | WO2004058770A8 Triptolide derivatives and their use |
| 07/14/2005 | WO2003059294A3 Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor |
| 07/14/2005 | WO2003029424A3 Novel proteins and nucleic acids encoding same |
| 07/14/2005 | US20050154165 Ph-sensitive polymer |
| 07/14/2005 | US20050154049 Administering an ultrasonic contrast agent; imaging tissue; medical diagnosis |
| 07/14/2005 | US20050154039 5-Sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine |
| 07/14/2005 | US20050154019 Substituted cyclic amine metalloprotease inhibitors |
| 07/14/2005 | US20050154017 Novel azasugar derivative and drug containing the same as the active ingredient |
| 07/14/2005 | US20050154015 Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 07/14/2005 | US20050154012 Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 07/14/2005 | US20050153992 Glycogen synthase kinase-3 inhibitors; pyrrolo[3,2-d]pyrimidine: neurodegenerative diseases; antidiabetic, antiinflammatory, anticancer agents; 5-(2-aminoethyl)-6-(3-chloro(2-thienyl))-7-iodo-3-hydropyrrolo[3,2-d]pyrimidin-4-thione Trifluoroacetate; 4-halo intermediates |
| 07/14/2005 | US20050153987 Compounds |
| 07/14/2005 | US20050153973 (4R)-3-(2-{[8-(2-Pyrimidinyl)-8-azabicyclo[3.2.1]oct-3-yl]exo-amino}acetyl)thiazolidine-4-carbonitrile; enzyme inhibitors; diabetes |
| 07/14/2005 | US20050153960 Substituted arylamine derivatives and methods of use |
| 07/14/2005 | US20050153941 Cell differntiation inhibiting agent, cell culture method using the same, culture medium, and cultured cell line |
| 07/14/2005 | US20050153917 Gene overexpression/underexpression; antibodies; drug screening; kits |
| 07/14/2005 | US20050153902 Inhibitors of integrin avb6 |
| 07/14/2005 | US20050153892 Compound B as an angiogenic agent in combination with human growth factors |
| 07/14/2005 | US20050153889 Modulation of pericyte proliferation |
| 07/14/2005 | US20050153886 nucleotide sequences comprising cDNA and genomic DNA that code for angiogenesis factors, used for gene therapy |
| 07/14/2005 | US20050152930 Parakeratosis inhibitor, pore-shrinking agent and skin preparation for external use |
| 07/14/2005 | US20050152865 Ceramide emulsions |
| 07/14/2005 | US20050152859 Inhibitors of melanocyte tyrosinase as topical skin lighteners |
| 07/14/2005 | US20050152856 0.5-7% by weight of D,L- alpha -lipoic acid, 0.05-0.5% by weight of coenzyme Q-10 and 0.01-3% by weight of acetyl-L-carnitine hydrochloride; treatment of visible sun injuries caused by processes involving the action of free radicals |
| 07/14/2005 | DE10360503A1 Kombinations- Set und Verfahren zur bioregenerativen Behandlung von Haut Combination kit and method for treatment of skin bioregenerative |
| 07/14/2005 | CA2552150A1 Means for stimulation and activation of hair growth by il-15 |
| 07/14/2005 | CA2550309A1 Canine probiotic bifidobacteria pseudolongum |
| 07/14/2005 | CA2550307A1 Canine probiotic bifidobacteria globosum |
| 07/14/2005 | CA2549703A1 Skin moisturizing agent for oral intake and functional foods and drinks |
| 07/13/2005 | EP1553101A1 N-acetylglucosamine derivatives and use thereof |
| 07/13/2005 | EP1553099A1 A riboflavin derivative and its manufacture and uses |
| 07/13/2005 | EP1553098A1 Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient |
| 07/13/2005 | EP1553097A1 Quinazoline derivatives as angiogenesis inhibitors and intermediates therefore |
| 07/13/2005 | EP1553096A1 Pyrazole compounds |
| 07/13/2005 | EP1553085A1 Cyclic amine derivatives and their use as drugs |
| 07/13/2005 | EP1553084A1 Piperidine derivative, process for producing the same, and use |
| 07/13/2005 | EP1552842A1 Bicyclic pyrimidine derivatives |
| 07/13/2005 | EP1552838A1 Rubrofusarin glycoside-containing composition |
| 07/13/2005 | EP1552837A1 Antipsoriatic agent |
| 07/13/2005 | EP1552827A1 Oral preventive/therapeutic agent for skin damage containing diacylglyceryl ether |
| 07/13/2005 | EP1551877A2 Taci antibodies and uses thereof |
| 07/13/2005 | EP1551865A2 Hybrid molcules of macrolides with steroid/non-steroid anti-inflammatory, antineoplastic and antiviral active molecules |
| 07/13/2005 | EP1551848A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors |
| 07/13/2005 | EP1551841A1 Pyrazolopyrimidines as kinase inhibitors |
| 07/13/2005 | EP1551840A1 1-heterocyclylalkyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
| 07/13/2005 | EP1551837A1 Phosphodiesterase 4 inhibitors |
| 07/13/2005 | EP1551792A1 Novel beta mimetics with extended duration of action, method for production and use thereof as medicaments |
| 07/13/2005 | EP1551791A1 Novel salt forms of poorly soluble probucol esters and ethers |
| 07/13/2005 | EP1551763A1 Method for the preparation of a silicic acid comprising extrudate, said extrudate, its use and a pharmaceutical composition comprising the said extrudate |
| 07/13/2005 | EP1551412A1 Pharmaceutical compositions for the treatment of diseases related to neurotrophines |
| 07/13/2005 | EP1551381A2 Styrylacrylonitrile compounds for inhibition of vascular endothelial growth factor |
| 07/13/2005 | EP1551369A2 Combination therapy for treatment of fibrotic disorders |
| 07/13/2005 | EP1551362A2 Use of amide or ester of sugar and of fatty acid, for treating and/or preventing dry skin. |
| 07/13/2005 | EP1448529B1 Sulfone derivatives suitable for the treatment of autoimmune diseases and allergies |
| 07/13/2005 | EP1161415B1 N-cyanomethylamides as protease inhibitors |
| 07/13/2005 | EP1144364B1 Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 07/13/2005 | CN1639317A Probiotic lactobacillus salivarius strains |
| 07/13/2005 | CN1639312A Immidazoline quats |
| 07/13/2005 | CN1639188A Hepta-, octa- and nonapeptides having antiangiogenic activity |
| 07/13/2005 | CN1639161A Alkyne-aryl phosphodiesterase-4 inhibitors |
| 07/13/2005 | CN1639159A N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as DDP-IV inhibitors |
| 07/13/2005 | CN1639139A 5-phenylthiazole derivatives and use as PI3 kinase inhibitors |
| 07/13/2005 | CN1639138A Biphenylmethyl-thiazolidinediones and analogues and their use as PPAR-gamma activators |
| 07/13/2005 | CN1639132A N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases |
| 07/13/2005 | CN1639130A Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same |
| 07/13/2005 | CN1639125A New inhibitors of histone deacetylase |
| 07/13/2005 | CN1639121A 3-azabicyclo (3.1.0) hexane derivatives having opioid receptor affinity |
| 07/13/2005 | CN1638822A Compositions comprising undifferentiated fetal cells for the treatment of skin disorders |
| 07/13/2005 | CN1638802A Percutaneous absorption promoters and compositions for treating athlete's foot |
| 07/13/2005 | CN1638800A Human monoclonal antibodies against CD30 |
| 07/13/2005 | CN1638799A Human mast cell-expressed membrane proteins |
| 07/13/2005 | CN1638796A Methods of administering anti-TNF alpha antibodies |
| 07/13/2005 | CN1638793A Pharmaceutical and cosmetic compositions comprising PLGF-1 |
| 07/13/2005 | CN1638790A Compositions and methods for modulating connexin hemichannels |
| 07/13/2005 | CN1638784A External compositions for the skin |
| 07/13/2005 | CN1638781A Carbon monoxide as a biomarker and therapeutic agent |
| 07/13/2005 | CN1638776A Substituted 3-aryl-5-aryl-[1, 2, 4]-oxadiazoles and analogs |
| 07/13/2005 | CN1638765A Mediators of Hedgehog signaling pathways, compositions and uses related thereto |
| 07/13/2005 | CN1638760A Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin |
| 07/13/2005 | CN1638753A Potentiation of therapeutic effects of fatty acids |
| 07/13/2005 | CN1638739A Compound for treating assuetude disturbance |
| 07/13/2005 | CN1638650A Composition improving age-related physiological deficits and increasing longevity |
| 07/13/2005 | CN1637015A 17alpha-alkyl-17beta-oxy-estratrienes, uses thereof and pharmaceutical preparations |
| 07/13/2005 | CN1636994A Process of preparing alkali metal salys of hydrophobic sulfonamides and alkali metal salt produced thereby |
| 07/13/2005 | CN1636992A Process for producing quinazoline ditosylate salt compounds |
| 07/13/2005 | CN1636983A Substituted heterocyclic compounds |
| 07/13/2005 | CN1636600A 皮肤外用制剂 External preparation for skin |
| 07/13/2005 | CN1636592A Stabilized liquid polypeptide-containing pharmaceutical composition |
| 07/13/2005 | CN1636586A Liniment for treating alopecia areata, seborrheic baldness and nerve baldness |
| 07/13/2005 | CN1636567A Piperazine derivative used as CCRS antagonist |
| 07/13/2005 | CN1636563A 噻唑衍生物 Thiazole derivatives |
| 07/13/2005 | CN1636561A Use of at-1 receptor antagonist for treating diseases associated with an increase of at-1 receptors |
| 07/13/2005 | CN1636550A Water-in-oil emulsion composition |
| 07/13/2005 | CN1636549A Oil-in-water emulsion composition |